GlassScriptPhysician profile
Christian M Dey
NPI 1275648412
$2,141.64
in general payments reported to CMS, 2019-2025
27 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $256 · 2021: $559 · 2022: $437 · 2023: $235 · 2024: $115 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $293.57 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $284.13 | 2020-2023 | Orilissa, Lo Loestrin Fe |
| Pfizer INC. | $240.61 | 2019-2024 | |
| Caldera Medical, INC | $148.44 | 2021 | |
| Agile Therapeutics, INC. | $122.97 | 2022-2023 | Twirla |
| Medtronic, INC. | $122.76 | 2025 | Auto Suture |
| Aspira Women'S Health INC | $105.46 | 2021 | |
| Hologic Sales and Service, LLC | $87.19 | 2019-2025 | Acessa Provu System, Aptima |
| Scynexis, INC. | $85.60 | 2022 | |
| Shield Therapeutics INC | $79.52 | 2023-2025 | Accrufer |
| Coopersurgical, INC. | $69.68 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $67.51 | 2022-2025 | |
| Amgen INC. | $60.92 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $55.44 | 2023-2025 | Gemtesa |
| Mylan Pharmaceuticals INC. | $46.96 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40.43 | 2020-2021 | |
| Urovant Sciences INC | $36.18 | 2022 | |
| Applied Medical Resources Corporation | $29.68 | 2024 | |
| Minerva Surgical, INC | $25.21 | 2019 | |
| Therapeuticsmd, INC. | $24.86 | 2020-2022 | |
| Organon LLC | $23.28 | 2022 | |
| Lilly USA, LLC | $19.20 | 2024 | Zepbound |
| Myovant Sciences INC. | $15.75 | 2022 | |
| Ethicon US, LLC | $15.59 | 2021 | |
| Evofem Biosciences, INC. | $14.82 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.99 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.89 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Dey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.